🇺🇸 FDA
Patent

US 12318426

Compositions and methods for the treatment of metabolic and liver disorders

granted A61KA61K38/16A61K47/542

Quick answer

US patent 12318426 (Compositions and methods for the treatment of metabolic and liver disorders) held by Viking Therapeutics, Inc. expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Viking Therapeutics, Inc.
Grant date
Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K38/16, A61K47/542, A61P, A61P1/16